These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24739994)

  • 21. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ; Shen JH; Chen Y; Lian YJ
    Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
    Sung Y; Nam SM; Lew H
    Korean J Ophthalmol; 2015 Apr; 29(2):115-20. PubMed ID: 25829828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
    Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
    Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IncobotulinumtoxinA for the Treatment of Blepharospasm in Toxin-Naïve Subjects: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial.
    Mitsikostas DD; Dekundy A; Sternberg K; Althaus M; Pagan F
    Adv Ther; 2020 Oct; 37(10):4249-4265. PubMed ID: 32779096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].
    Kurenkov AL; Klochkova OA; Bursagova BI; Karimova HM; Kuzenkova LM; Mamedyarov AM; Namazova-Baranova LS; Agranovich OV; Agranovich AO; Soboleva OA; Khapaeva MM; Batysheva TT; Sarzhina MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):37-44. PubMed ID: 29265085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
    Girard B; de Saint Sauveur G
    J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.
    Park J; Lee MS; Harrison AR
    Clin Ophthalmol; 2011; 5():725-32. PubMed ID: 21691580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.
    Lee S; Park S; Lew H
    Korean J Ophthalmol; 2018 Feb; 32(1):1-7. PubMed ID: 29376224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
    Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
    J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.
    Kollewe K; Mohammadi B; Köhler S; Pickenbrock H; Dengler R; Dressler D
    J Neural Transm (Vienna); 2015 Mar; 122(3):427-31. PubMed ID: 25059456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA.
    Ricciardi L; Ialongo T; Guidubaldi A; Di Giacopo R; Bentivoglio AR
    Parkinsonism Relat Disord; 2014 Jun; 20(6):665-7. PubMed ID: 24685658
    [No Abstract]   [Full Text] [Related]  

  • 36. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
    Zhou Y; Wang W; Lin Z; Lin T; Gong L
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
    Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.